Marisol Quintero
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025
Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.
Journal: Cancer discovery
Published: June 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2025
Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results.
Journal: Cancer discovery
Published: June 27, 2025
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
Journal: Journal for immunotherapy of cancer
Published: April 03, 2024
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic.
Journal: Oncoimmunology
Published: April 10, 2023
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.
Journal: Journal for immunotherapy of cancer
Published: September 26, 2022
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
Journal: Journal for immunotherapy of cancer
Published: September 28, 2021
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
Journal: Science translational medicine
Published: January 24, 2020
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.
Journal: Science translational medicine
Published: January 24, 2020
Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026